371 related articles for article (PubMed ID: 17245449)
1. Cost-effectiveness of genotypic antiretroviral resistance testing in HIV-infected patients with treatment failure.
Sendi P; Günthard HF; Simcock M; Ledergerber B; Schüpbach J; Battegay M;
PLoS One; 2007 Jan; 2(1):e173. PubMed ID: 17245449
[TBL] [Abstract][Full Text] [Related]
2. A longitudinal analysis of healthcare costs after treatment optimization following genotypic antiretroviral resistance testing: does resistance testing pay off?
Simcock M; Sendi P; Ledergerber B; Keller T; Schüpbach J; Battegay M; Günthard HF;
Antivir Ther; 2006; 11(3):305-14. PubMed ID: 16759046
[TBL] [Abstract][Full Text] [Related]
3. Cost effectiveness analysis of routine use of genotypic antiretroviral resistance testing after failure of antiretroviral treatment for HIV.
Corzillius M; Mühlberger N; Sroczynski G; Jaeger H; Wasem J; Siebert U
Antivir Ther; 2004 Feb; 9(1):27-36. PubMed ID: 15040534
[TBL] [Abstract][Full Text] [Related]
4. When to initiate highly active antiretroviral therapy in sub-Saharan Africa? A South African cost-effectiveness study.
Badri M; Cleary S; Maartens G; Pitt J; Bekker LG; Orrell C; Wood R
Antivir Ther; 2006; 11(1):63-72. PubMed ID: 16518961
[TBL] [Abstract][Full Text] [Related]
5. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of chemoprophylaxis after occupational exposure to HIV.
Pinkerton SD; Holtgrave DR; Pinkerton HJ
Arch Intern Med; 1997 Sep; 157(17):1972-80. PubMed ID: 9308509
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy.
Sanders GD; Bayoumi AM; Sundaram V; Bilir SP; Neukermans CP; Rydzak CE; Douglass LR; Lazzeroni LC; Holodniy M; Owens DK
N Engl J Med; 2005 Feb; 352(6):570-85. PubMed ID: 15703422
[TBL] [Abstract][Full Text] [Related]
8. Use of genotypic resistance testing to guide hiv therapy: clinical impact and cost-effectiveness.
Weinstein MC; Goldie SJ; Losina E; Cohen CJ; Baxter JD; Zhang H; Kimmel AD; Freedberg KA
Ann Intern Med; 2001 Mar; 134(6):440-50. PubMed ID: 11255519
[TBL] [Abstract][Full Text] [Related]
9. How does expert advice impact genotypic resistance testing in clinical practice?
Badri SM; Adeyemi OM; Max BE; Zagorski BM; Barker DE
Clin Infect Dis; 2003 Sep; 37(5):708-13. PubMed ID: 12942405
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness analysis of lopinavir/ritonavir and atazanavir+ritonavir regimens in the CASTLE study.
Simpson KN; Rajagopalan R; Dietz B
Adv Ther; 2009 Feb; 26(2):185-93. PubMed ID: 19219410
[TBL] [Abstract][Full Text] [Related]
11. The costs and benefits of private sector provision of treatment to HIV-infected employees in Kampala, Uganda.
Marseille E; Saba J; Muyingo S; Kahn JG
AIDS; 2006 Apr; 20(6):907-14. PubMed ID: 16549976
[TBL] [Abstract][Full Text] [Related]
12. Genotypic resistance tests in the management of the HIV-infected patient at virological failure.
Aceti A; Carosi G
Scand J Infect Dis Suppl; 2003; 106():61-6. PubMed ID: 15000587
[TBL] [Abstract][Full Text] [Related]
13. A health economic analysis of screening and optimal treatment of nephropathy in patients with type 2 diabetes and hypertension in the USA.
Palmer AJ; Valentine WJ; Chen R; Mehin N; Gabriel S; Bregman B; Rodby RA
Nephrol Dial Transplant; 2008 Apr; 23(4):1216-23. PubMed ID: 18359872
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of optimized background therapy plus maraviroc for previously treated patients with R5 HIV-1 infection from the perspective of the Spanish health care system.
Moreno S; González J; Lekander I; Martí B; Oyagüez I; Sánchez-de la Rosa R; Casado MA
Clin Ther; 2010 Dec; 32(13):2232-45. PubMed ID: 21316539
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness and cost effectiveness of early and late prevention of HIV/AIDS progression with antiretrovirals or antibiotics in Southern African adults.
Bachmann MO
AIDS Care; 2006 Feb; 18(2):109-20. PubMed ID: 16338768
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of clinical interventions for AIDS wasting.
Beaston-Blaakman A; Shepard DS; Stone N; Shevitz AH
AIDS Care; 2007 Sep; 19(8):996-1001. PubMed ID: 17851996
[TBL] [Abstract][Full Text] [Related]
17. Economics of switching to second-line antiretroviral therapy with lopinavir/ritonavir in Africa: estimates based on DART trial results and costs for Uganda and Kenya.
Simpson KN; Baran RW; Kirbach SE; Dietz B
Value Health; 2011 Dec; 14(8):1048-54. PubMed ID: 22152173
[TBL] [Abstract][Full Text] [Related]
18. The long-term benefits of genotypic resistance testing in patients with extensive prior antiretroviral therapy: a model-based approach.
Yazdanpanah Y; Vray M; Meynard J; Losina E; Weinstein MC; Morand-Joubert L; Goldie SJ; Hsu HE; Walensky RP; Dalban C; Sax PE; Girard PM; Freedberg KA
HIV Med; 2007 Oct; 8(7):439-50. PubMed ID: 17760736
[TBL] [Abstract][Full Text] [Related]
19. The use of resistance testing in the management of HIV-1-infected patients.
Grant PM; Zolopa AR
Curr Opin HIV AIDS; 2009 Nov; 4(6):474-80. PubMed ID: 20048713
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of laboratory monitoring for management of HIV treatment in sub-Saharan Africa: a model-based analysis.
Hamers RL; Sawyer AW; Tuohy M; Stevens WS; Rinke de Wit TF; Hill AM;
AIDS; 2012 Aug; 26(13):1663-72. PubMed ID: 22695297
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]